Dermatology

Achieving the primary end point, 44.6% and 54.3% of patients treated with upadacitinib (15 mg and 30 mg) reached 80% or more scalp hair coverage.

Nektar Therapeutics remains on track to announce top-line phase 2 data in December.

The study enrolled infants not selected for risk, a population that has been seldom studied with regard to emollient intervention.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Study links early childhood eczema timing to risk of allergies like food allergy, asthma, and rhinitis, with five distinct disease phenotypes identified.

John Browning, MD, highlights the importance of fragrance-free, steroid-free creams in managing atopic dermatitis safely and effectively in children.

J&J is seeking the first approval for the investigational targeted oral peptide to treat patients 12 years or older with moderate to severe plaque psoriasis.

His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Roflumilast cream 0.05% is being studied for mild to moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate to severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

Pediatric dermatologist John Browning, MD, offers practical sun safety tips and guidance for selecting sunscreens, emphasizing the importance of choosing formulations that work for sensitive skin.

John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent nonsteroidal medications and what questions to ask patients in the office.

The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

Infant is closely monitored at subsequent well visits and rechecked after 3 months, showed full resolution of the skin lesion over the heel area.

Review some of the reactions from experts about the recent FDA approval of roflumilast foam 0.3% to treat scalp and body psoriasis in patients aged 12 years or older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.

Mona Shahriari, MD, discusses how RAD 2025 can equip providers with tools to improve atopic dermatitis outcomes.

The decision makes pz-cel the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.